ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

J&J and BARDA advance coronavirus vaccine

by Michael McCoy
April 3, 2020 | APPEARED IN VOLUME 98, ISSUE 13

 

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

Johnson & Johnson says it has identified a lead vaccine candidate for the new coronavirus that it will develop in partnership with the US Biomedical Advanced Research and Development Authority (BARDA). J&J began developing the vaccine in January, as soon as the virus’s sequence became available. The firm says it and BARDA are willing to spend more than $1 billion to get the adenoviral vaccine into human clinical studies by September and available for emergency use in early 2021.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment